Cargando…

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy

BACKGROUND: The ribonucleotide reductase M1 (RRM1) gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine. The overexpression of RRM1 mRNA in tumor tissues is reported to be associated with gemcitabine resistance. Thus, single nucleotide polymorphisms (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Song, Guo, Ai-Lin, Chen, Zhi-Hong, Wang, Zhen, Zhang, Xu-Chao, Huang, Ying, Xie, Zhi, Yan, Hong-Hong, Cheng, Hua, Wu, Yi-Long
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855513/ https://www.ncbi.nlm.nih.gov/pubmed/20226083 http://dx.doi.org/10.1186/1756-8722-3-10

Ejemplares similares

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Prediction of the Impact of Deleterious Nonsynonymous Single Nucleotide Polymorphisms on the Human RRM2B Gene: A Molecular Modeling Study
por: Ait El Cadi, Chaimaa, et al.
Publicado: (2020)

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells
por: Kato, Tomotaka, et al.
Publicado: (2021)

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2023)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine
por: Mlak, Radosław, et al.
Publicado: (2018)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs
por: Sheng, Jin, et al.
Publicado: (2016)

Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
por: Wang, Hao, et al.
Publicado: (2021)

Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma
por: Liu, Jian-Ye, et al.
Publicado: (2013)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Hong, Shaodong, et al.
Publicado: (2016)

XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Independent prognostic implications of RRM2 in lung adenocarcinoma
por: Ma, Chao, et al.
Publicado: (2020)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2021)

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer
por: Song, Xiao, et al.
Publicado: (2017)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy
por: Yang, Shih-Hung, et al.
Publicado: (2017)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)

The nature of the modification at position 37 of tRNA(Phe) correlates with acquired taxol resistance
por: Pan, Yu, et al.
Publicado: (2020)

Computed tomography radiomics signature via machine learning predicts RRM2 and overall survival in hepatocellular carcinoma
por: Li, Qian, et al.
Publicado: (2023)

The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer
por: Gandhi, Minakshi, et al.
Publicado: (2020)

The single nucleotide variant at c.662A>G in human RRM2B is a loss‐of‐function mutation
por: Tseng, Yen‐Tzu, et al.
Publicado: (2020)

RRM1 variants cause a mitochondrial DNA maintenance disorder via impaired de novo nucleotide synthesis
por: Shintaku, Jonathan, et al.
Publicado: (2022)

Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
por: Chang, Runsheng, et al.
Publicado: (2023)

Association between single nucleotide polymorphisms of NOTCH signaling pathway-related genes and the prognosis of NSCLC
por: Xu, Qiuping, et al.
Publicado: (2019)

Structural basis of IMP3 RRM12 recognition of RNA
por: Jia, Min, et al.
Publicado: (2018)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy
por: Yu, Shu-Lin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eofs1mt25pk5e26tqs1d04p7h6